Science Advances · 2020 · 35 citations · 41 references
Life SciencesMolecular BiologyOncologyDna RepairDrug DiscoveryMolecular OncologyCancer Cell SignalingDna Damage SignalingOncogenic Signaling PathwaysSignal Transduction In CancerSynthetic LethalitySynthetic Lethality In CancerChromatin RemodelingDna Damage Response InhibitorsDna Damage Response TargetingGenotoxic Stress ResponseMtor InhibitionMtor SignalingSynthetic Lethality ResistanceTherapeutic Targeting Of Myc
Despite considerable efforts, mTOR inhibitors have produced limited success in the clinic. To define the vulnerabilities of mTORC1-addicted cancer cells and to find previously unknown therapeutic targets, we investigated the mechanism of piperlongumine, a small molecule identified in a chemical library screen to specifically target cancer cells with a hyperactive mTORC1 phenotype. Sensitivity to piperlongumine was dependent on its ability to suppress RUVBL1/2-TTT, a complex involved in chromatin remodeling and DNA repair. Cancer cells with high mTORC1 activity are subjected to higher levels of DNA damage stress via c-Myc and displayed an increased dependency on RUVBL1/2 for survival and counteracting genotoxic stress. Examination of clinical cancer tissues also demonstrated that high mTORC1 activity was accompanied by high RUVBL2 expression. Our findings reveal a previously unknown role for RUVBL1/2 in cell survival, where it acts as a functional chaperone to mitigate stress levels induced in the mTORC1-Myc-DNA damage axis.
41
TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling
Ken Inoki, Yong Li, Tianquan Zhu et al. · Nature Cell Biology · 2002 · 3.1K citations
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
Ji Luo, Nicole L. Solimini, Stephen J. Elledge · Cell · 2009 · 1.8K citations · Full text
Medicine, Cancer Biology, Oncology +14
The translational landscape of mTOR signalling steers cancer initiation and metastasis
Andrew C. Hsieh, Yi Liu, Merritt P. Edlind et al. · Nature · 2012 · 1.4K citations
Medicine, Cancer Biology, Oncology +14